4.5 Article

Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study

Journal

CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 202, Issue 3, Pages 321-324

Publisher

OXFORD UNIV PRESS
DOI: 10.1111/cei.13499

Keywords

anti-acetylcholine receptor antibody; biomarker; disease activity; myasthenia gravis; neuromuscular junction; urokinase plasminogen activator receptor

Categories

Ask authors/readers for more resources

Myasthenia gravis (MG) is an autoantibody-mediated inflammatory disease of the neuromuscular junction. Biomarkers indicating disease activity in MG are warranted. Recently, the soluble urokinase plasminogen activator receptor (suPAR) has been reported to be associated with inflammation, tissue damage, disease activity and prognosis in various diseases, including autoimmune diseases. In this study, serum suPAR levels were measured in 40 patients with anti-acetylcholine receptor antibody-positive MG and 30 controls, and their correlations with clinical variables and severity scale scores were investigated. We identified that serum suPAR levels significantly correlated with MG activities of daily living scale (Spearman's rho = 0.45;P = 0.004) and MG Foundation of America classification (Spearman's rho = 0.37;P = 0.02) at serum sampling, but not with anti-acetylcholine receptor antibody titers. In conclusion, serum suPAR levels can be a candidate for a novel biomarker of disease activity in anti-acetylcholine receptor antibody-positive MG.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available